No results for ‘’
Marksans Pharma Ltd
₹329.40
(0.30%)
Mon, 21 Sept 2026, 01:55 pm
Health Technology
Pharmaceuticals: Major
24.5KMarksans Pharma Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 35.68 | 27.74 | 43.14 | 0 | 0 | 0 | 0 | 3.28 | 12.81 | 23.26 | 24.06 | 214.32 | 39.33 | 13.30 | 4.86 | 8.67 | 10.10 | 11 | 21.89 | 26.48 |
| Price to book ratio | 7.71 | 1.62 | 5.19 | 1.11 | 1.22 | 0 | 0 | 2.06 | 7.17 | 6.87 | 4.28 | 4.45 | 2.75 | 1.87 | 0.89 | 2.31 | 1.55 | 1.83 | 3.33 | 4.08 |
| Price to sales ratio | 2.82 | 0.79 | 2.59 | 0.43 | 0.50 | 0.27 | 0.18 | 0.34 | 1.47 | 3.18 | 2.14 | 2.52 | 1.43 | 1.03 | 0.50 | 1.49 | 1.26 | 1.58 | 3.16 | 3.85 |
| Price to cash flow ratio | 0 | 0 | 28.29 | 10.83 | 28.59 | 0 | 0 | 5.35 | 16.73 | 16.93 | 56.67 | 135.73 | 32.41 | 57.05 | 2.53 | 11.91 | 19.44 | 12.11 | 26.82 | 42.32 |
| Enterprise value | 936Cr | 357Cr | 956Cr | 541Cr | 582Cr | 545Cr | 526Cr | 385Cr | 1118Cr | 2447Cr | 1964Cr | 2032Cr | 1393Cr | 1104Cr | 523Cr | 1885Cr | 1646Cr | 2356Cr | 6432Cr | 9715Cr |
| Enterprise value to EBITDA ratio | 21.22 | 23.04 | 29.89 | 18.46 | 23.82 | 35.92 | 11.93 | 5.96 | 9.94 | 13.69 | 16.05 | 61.73 | 19.57 | 9.15 | 2.78 | 5.63 | 6.56 | 6.70 | 13.97 | 18.33 |
| Debt to equity ratio | 2.53 | 2.52 | 2.38 | 2.64 | 2.63 | 0 | 0 | 2.66 | 1.56 | 0.23 | 0.19 | 0.28 | 0.27 | 0.20 | 0.05 | 0.04 | 0.09 | 0.07 | 0.12 | 0.13 |
| Return on equity % | 20.65 | 5.37 | 11.49 | -5.72 | -6.45 | -465.22 | 0 | 0 | 62.89 | 41.92 | 18.83 | 1.99 | 7.29 | 15.09 | 19.86 | 30.99 | 17.67 | 18.07 | 16.47 | 16.80 |
Marksans Pharma Ltd Enterprise Value
The Marksans Pharma Ltd Enterprise Value is a key financial metric used by investors to evaluate Marksans Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Marksans Pharma Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Marksans Pharma Ltd (NSE: MARKSANS, BSE: 524404) is currently trading at ₹329.40, with a market capitalization of ₹14974.8Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Marksans Pharma Ltd Enterprise Value is essential for fundamental analysis.
Marksans Pharma Ltd Enterprise Value Current Value
The current Marksans Pharma Ltd Enterprise Value stands at 9715Cr.
The latest Marksans Pharma Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Marksans Pharma Ltd Enterprise Value Historical Trend
The Marksans Pharma Ltd Enterprise Value has shown the following historical trend:
- 2024: 9715Cr
- 2023: 6432Cr
- 2022: 2356Cr
- 2021: 1646Cr
- 2020: 1885Cr
The recent rise in Marksans Pharma Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Marksans Pharma Ltd Enterprise Value Indicates for Investors
The Marksans Pharma Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Marksans Pharma Ltd.
Marksans Pharma Ltd Enterprise Value Analysis Summary
The Marksans Pharma Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Marksans Pharma Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Marksans Pharma Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.